Full text links CiteDisplay options Display options Format AbstractPubMedPMID
Abstract
We describe a case of chronic coronavirus disease 2019 (COVID-19) in a patient with lymphoma and associated B-cell immunodeficiency. Viral cultures and sequence analysis demonstrate ongoing replication of infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for at least 119 days. The patient had 3 admissions related to COVID-19 over a 4-month period and was treated twice with remdesivir and convalescent plasma with resolution of symptoms. The patient's lack of seroconversion and prolonged course illustrate the importance of humoral immunity in resolving SARS-CoV-2 infection. This case highlights challenges in managing immunocompromised hosts, who may act as persistent shedders and sources of transmission.
A , Timeline of case. Color is by stage of infection, orange (initial… Figure 1. A, Timeline of case. Color is by stage of infection, orange (initial presentation); yellow (largely outpatient); purple (recrudescence and readmission). Key events and treatments are shown above the timeline and key laboratory values are shown below it. B, Immunofluorescence microscopy of viral cultures. The patient’s samples (days 106 and 119) and a positive control (WA-1 strain) viral stock were cultured on Vero E6 cells until cytopathic effect was observed. Huh-7 cells were infected with cell-free supernatants from the Vero E6 cultures and stained 48 hours later with Hoechst (blue, nuclei) and an anti–severe acute respiratory syndrome coronavirus 2 nucleocapsid antibody (magenta). C, Maximum likelihood phylogenetic tree of whole genome consensus sequences for 9 samples from this case (red tips) and 100 other samples from inpatients at the same hospital (see Supplementary Table 1, color coded by lineage). Tree is rooted to Wuhan-Hu-1. Bootstrap support (1000 replicates) at nodes for the samples from the case and for all lineages is >90. D, Consensus mutations in the 9 samples sequenced. All nucleotide substitutions are shown. Amino acid substitutions are indicated for all nonsynonymous substitutions. Mutations in blue were in the original day 7 sample and persisted. Mutations in orange were detected in 1 of 2 day 29 samples and then at days 93 and 106. Mutations in purple were first detected in the day 93 sample and persisted at day 106. Mutations in red were fixed in the day 106 sample only. Abbreviations: Ct, cycle threshold; E, envelope; IgG, immunoglobulin G; ND, not detected; NP, nasopharyngeal; ORF, open reading frame; S, spike. See this image and copyright information in PMC
Similar articles
Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir. Camprubí D, Gaya A, Marcos MA, Martí-Soler H, Soriano A, Mosquera MDM, Oliver A, Santos M, Muñoz J, García-Vidal C.Camprubí D, et al.Int J Infect Dis. 2021 Mar;104:379-381. doi: 10.1016/j.ijid.2020.12.050. Epub 2020 Dec 21.Int J Infect Dis. 2021.PMID: 33359065Free PMC article.
Impaired immune responses and prolonged viral replication in lung allograft recipients infected with SARS-CoV-2 in the early phase after transplantation. Glueck OM, Liang X, Badell I, Wratil PR, Graf A, Krebs S, Blum H, Hellmuth JC, Scherer C, Hollaus A, Spaeth PM, Karakoc B, Fuchs T, Zimmermann J, Kauke T, Moosmann A, Keppler OT, Schneider C, Muenchhoff M.Glueck OM, et al.Infection. 2024 Jun;52(3):847-855. doi: 10.1007/s15010-023-02116-6. Epub 2023 Nov 3.Infection. 2024.PMID: 37922037Free PMC article.
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Buckland MS, Galloway JB, Fhogartaigh CN, Meredith L, Provine NM, Bloor S, Ogbe A, Zelek WM, Smielewska A, Yakovleva A, Mann T, Bergamaschi L, Turner L, Mescia F, Toonen EJM, Hackstein CP, Akther HD, Vieira VA, Ceron-Gutierrez L, Periselneris J, Kiani-Alikhan S, Grigoriadou S, Vaghela D, Lear SE, Török ME, Hamilton WL, Stockton J, Quick J, Nelson P, Hunter M, Coulter TI, Devlin L; CITIID-NIHR COVID-19 BioResource Collaboration; MRC-Toxicology Unit COVID-19 Consortium; Bradley JR, Smith KGC, Ouwehand WH, Estcourt L, Harvala H, Roberts DJ, Wilkinson IB, Screaton N, Loman N, Doffinger R, Lyons PA, Morgan BP, Goodfellow IG, Klenerman P, Lehner PJ, Matheson NJ, Thaventhiran JED.Buckland MS, et al.Nat Commun. 2020 Dec 14;11(1):6385. doi: 10.1038/s41467-020-19761-2.Nat Commun. 2020.PMID: 33318491Free PMC article.
Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. Nili A, Farbod A, Neishabouri A, Mozafarihashjin M, Tavakolpour S, Mahmoudi H.Nili A, et al.Rev Med Virol. 2020 Nov;30(6):1-13. doi: 10.1002/rmv.2133. Epub 2020 Jul 30.Rev Med Virol. 2020.PMID: 33210457Review.
COVID-19-related Pneumonitis in Immunocompromised Patients: Reviewing Clinical Features and Management Approaches. Nasrullah A, Shakir H, Khan E, Bilal MI, Sheikh AB, Malik K, Cheema T.Nasrullah A, et al.J Community Hosp Intern Med Perspect. 2024 Sep 9;14(5):63-72. doi: 10.55729/2000-9666.1399. eCollection 2024.J Community Hosp Intern Med Perspect. 2024.PMID: 39399191Free PMC article.Review.
Persistent COVID-19 Infection in an Immunocompromised Host: A Case Report. Das R, Karyakarte RP, Joshi S, Joy M, Sadre A.Das R, et al.Cureus. 2024 Sep 4;16(9):e68679. doi: 10.7759/cureus.68679. eCollection 2024 Sep.Cureus. 2024.PMID: 39371780Free PMC article.
Effectiveness of heterologous and homologous COVID-19 vaccination among immunocompromised individuals: a systematic literature review and meta-analysis. Pardo I, Maezato AM, Callado GY, Gutfreund MC, Hsieh MK, Lin V, Kobayashi T, Salinas JL, Subramanian A, Edmond MB, Diekema DJ, Rizzo LV, Marra AR.Pardo I, et al.Antimicrob Steward Healthc Epidemiol. 2024 Sep 26;4(1):e152. doi: 10.1017/ash.2024.369. eCollection 2024.Antimicrob Steward Healthc Epidemiol. 2024.PMID: 39346662Free PMC article.
A case report of prolonged viral shedding of SARS-CoV-2 in a patient who receive ibrutinib for CLL therapy. Ma S, Wei D, Hu W, Xi M, Zhang Y, Chen X, Chen J.Ma S, et al.BMC Infect Dis. 2024 Sep 2;24(1):895. doi: 10.1186/s12879-024-09794-z.BMC Infect Dis. 2024.PMID: 39218877Free PMC article.
Recurrent Cytokine Storm in SARS-CoV-2 Infected Patients with Hematolymphoid Malignancy: A New Perspective. Kamtalwar S, Mirgh S, More A, Sharma P, Patkar N, Rajpal S, Chatterjee G, Shetty N, Gokarn A.Kamtalwar S, et al.South Asian J Cancer. 2023 Aug 11;13(2):157-162. doi: 10.1055/s-0043-1761443. eCollection 2024 Apr.South Asian J Cancer. 2023.PMID: 38919664Free PMC article.No abstract available.
See all "Cited by" articles
References
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324:782–93. - PubMed
Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients [manuscript published online ahead of print 19 August 2020]. Clin Infect Dis 2020. doi:10.1093/cid/ ciaa460. - PMC - PubMed
Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples [manuscript published online ahead of print 22 May 2020]. Clin Infect Dis 2020. doi:10.1093/cid/ ciaa638. - PubMed
Rhee C, Kanjilal S, Baker M, Klompas M. Duration of SARS-CoV-2 infectivity: when is it safe to discontinue isolation? [manuscript published online ahead of print August 25 2020]. Clin Infect Dis 2020. doi:10.1093/cid/ ciaa1249. - PMC - PubMed
Randall RE, Griffin DE. Within host RNA virus persistence: mechanisms and consequences. Curr Opin Virol 2017; 23:35–42. - PMC - PubMed
